Skip to content
Acceleron Pharma

Investors/Media

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Nov 1, 2007
Cambridge, Mass. – November 1, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that it will provide a corporate presentation at the Massachusetts Biotechnology Council’s (MBC) 9th Annual MASS ...
Oct 31, 2007
BioWorld Today, October 31, 2007
Oct 31, 2007
Cambridge, Mass. – October 31, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron, will provide a corporate presentation at the Acumen Bio...
Oct 30, 2007
Cambridge, Mass. – October 30, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced it raised $31M in a Series C financing. Bessemer Venture Partners led the round along with other new investors MPM BioE...
Oct 18, 2007
Link to article
Oct 18, 2007
Cambridge, Mass. – October 18, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced results of a preclinical study with ACE-031, the company’s lead product for the treatment of muscular dystrophy, ...
Oct 4, 2007
Cambridge, Mass. – October 4, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, announced that the Web Marketing Association (“WMA”) awarded a “Pharmaceutical Industry Standard of Excellence”...
Oct 2, 2007
Cambridge, Mass. – October 2, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron, will provide a corporate presentation at the Natixis Bleic...
Sep 24, 2007
Cambridge, Mass. – September 24, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that Niels Borgstein, M.D. has joined Acceleron as Vice President, Medical Research. Dr. Borgstein has more than 10...
Sep 20, 2007
Cambridge, Mass. – September 20, 2007 - Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John Knopf, Ph.D., Chief Executive Officer of Acceleron, will provide a corporate presentation at the UBS 2007 Global ...
Sep 20, 2007
Cambridge, Mass. – September 20, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that ACE-011 improved bone microarchitecture, increased bone mineral density and bone mechanical strength. The result...
Sep 18, 2007
Honolulu, HI – September 18, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced positive results for the phase 1 clinical trial of ACE-011 at The American Society for Bone and Mineral Research (ASBMR) ...
Sep 18, 2007
Cambridge, MA – September 18, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced that John L. Knopf, Ph.D., has been named as the Chief Executive Officer of Acceleron. Dr. Knopf has also been elected t...
Aug 6, 2007
CAMBRIDGE, MA – August 6, 2007 – Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced it will present the final results for the phase 1 clinical trial of ACE-011, its novel anabolic therapy for the treatment of...
Aug 1, 2007
Pharmaceutical Executive, August 1, 2007
= add release to Briefcase